APP and Alzheimer disease: In the APP/PS1 mouse model of AD, metformin activates CMA via the TAK1-IKKα/β-Hsc70 signalling pathway and effectively reduces the accumulated brain Aβ plaques, providing a therapeutic effect in AD (Xu et al., 2021).